Study population and treatment
NSCLC, chemotherapy-naive
NON-SMALL CELL LUNG CANCER, NSCLC
Eligible patients were ≥ 18 years of age with a confirmed diagnosis of non-small cell lung cancer (NSCLC), chemotherapy-naive and scheduled to receive the first course of cisplatin (≥ 70 mg/m